Consumer medicine information

DBL Ephedrine Sulfate Injection

Ephedrine sulfate

BRAND INFORMATION

Brand name

DBL Ephedrine Sulfate Injection

Active ingredient

Ephedrine sulfate

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using DBL Ephedrine Sulfate Injection.

SUMMARY CMI

DBL™ Ephedrine Sulfate Injection

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I being treated with DBL Ephedrine Sulfate Injection?

DBL Ephedrine Sulfate Injection contains the active ingredient ephedrine sulfate. DBL Ephedrine Sulfate is used to treat some forms of shock, low blood pressure that occurs when a local anaesthetic is given around the spinal cord, and in the treatment of asthma and spasm of the airways.

For more information, see Section 1. Why am I being treated with DBL Ephedrine Sulfate Injection? in the full CMI.

2. What should I know before treatment with DBL Ephedrine Sulfate Injection?

DBL Ephedrine Sulfate Injection should not be used if you have ever had an allergic reaction to ephedrine sulfate; have closed angle glaucoma, pheochromocytoma, certain problems with the heart or heart rate, an anxiety disorder with obsessive behaviours; have taken monoamine oxidase inhibitors within the last 14 days.

Talk to your doctor if you have any other medical conditions, take any other medicines, are pregnant or breastfeeding.

For more information, see Section 2. What should I know before treatment with DBL Ephedrine Sulfate Injection? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with DBL Ephedrine Sulfate Injection and affect how it works. Examples include medicines used to treat high blood pressure, manage depression, make urine less acidic, treat heart failure, or treat asthma and other related lung problems.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How is DBL Ephedrine Sulfate Injection given?

Your doctor will give you DBL Ephedrine Sulfate Injection by injection into a muscle, vein, or under the skin and decide how much you will be given and for how long.

More instructions can be found in Section 4. How is DBL Ephedrine Sulfate given? in the full CMI.

5. What should I know during treatment with DBL Ephedrine Sulfate Injection?

Things you should do
  • Remind any doctor or nurse that you have been given DBL Ephedrine Sulfate Injection.
Driving or using machines
  • Your doctor will tell you when it is safe to drive and operate potentially dangerous machinery after you have been given DBL Ephedrine Sulfate Injection.
Drinking alcohol
  • No information available.
Looking after your medicine
  • The hospital will appropriately store and dispose of this medicine.

For more information, see Section 5. What should I know during treatment with DBL Ephedrine Sulfate Injection? in the full CMI.

6. Are there any side effects?

Side effects include sudden life-threatening allergic reactions (shortness of breath, wheezing or difficulty breathing; swelling of the face, lips, tongue, or other parts of the body; rash, itching or hives on the skin); difficult or painful urination/weeing; feeling sick; an upset stomach or vomiting; a feeling of pain or pressure in the chest; difficulty breathing or shortness of breath; a fast, slow or irregular heartbeat; dizziness; lightheadedness; pale skin; fever or sweating; headache; a dry nose, mouth and throat; difficulty sleeping; mood changes; irritability; nervousness; restlessness; abnormal thoughts; confusion.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.



FULL CMI

DBL™ Ephedrine Sulfate Injection

Active ingredient(s): ephedrine sulfate

Consumer Medicine Information (CMI)

This leaflet provides important information about using DBL Ephedrine Sulfate Injection. You should also speak to your doctor, nurse or pharmacist if you would like further information or if you have any concerns or questions about treatment with DBL Ephedrine Sulfate Injection.

Where to find information in this leaflet:

1. Why am I being treated with DBL Ephedrine Sulfate Injection?
2. What should I know before treatment with DBL Ephedrine Sulfate Injection?
3. What if I am taking other medicines?
4. How is DBL Ephedrine Sulfate Injection given?
5. What should I know during treatment with DBL Ephedrine Sulfate Injection?
6. Are there any side effects?
7. Product details

1. Why am I being treated with DBL Ephedrine Sulfate Injection?

DBL Ephedrine Sulfate Injection contains the active ingredient ephedrine sulfate. DBL Ephedrine Sulfate Injection is a type of medicine called a sympathomimetic agent. You may also hear it referred to as a pressor when used to raise blood pressure. DBL Ephedrine Sulfate Injection works by activating the sympathetic nervous system which leads to relaxation of the muscles in your airway, contraction of blood vessels and stimulation of the heart.

DBL Ephedrine Sulfate Injection is used to treat some forms of shock, low blood pressure that occurs when a local anaesthetic is given around the spinal cord, and in the treatment of asthma and spasm of the airways.

2. What should I know before treatment with DBL Ephedrine Sulfate Injection?

Warnings

DBL Ephedrine Sulfate Injection should not be used if you have:

  • an allergy to ephedrine sulfate
  • closed angle glaucoma (a buildup of pressure in the eye due to a blockage),
  • pheochromocytoma (a rare tumour of the adrenal gland, which sits near the kidneys),
  • certain problems with the heart or heart rate,
  • taking or have taken monoamine oxidase (MAO) inhibitors within the last 14 days, e.g. phenelzine or tranylcypromine
  • an anxiety disorder including obsessive behaviours.

Check with your doctor if you have:

  • kidney problems or weakness, tiredness, dizziness and increased thirst,
  • too much acid in your blood (metabolic acidosis) causing nausea, vomiting, drowsiness and breathlessness
  • lung problems or difficulty breathing
  • problems with your heart, including angina
  • high blood pressure
  • overactive thyroid
  • diabetes
  • problems urinating/weeing or prostate problems if you are a man.

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Check with your doctor if you are pregnant.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

DBL Ephedrine Sulfate Injection has been shown to pass into breast milk. Discuss breastfeeding during this period with your doctor.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may affect or be affected by DBL Ephedrine Sulfate Injection. These include:

  • alpha blockers or beta blockers and other medicines used to treat high blood pressure, e.g. prazosin, propranolol, methyldopa, clonidine
  • medicines used to manage depression such as tricyclic antidepressants (TCAs), e.g. amitriptyline, clomipramine, dothiepin, imipramine
  • medicines to make urine less acidic, e.g. acetazolamide, dichlorphenamide, sodium bicarbonate, sodium citrate
  • medicines used during anaesthesia e.g. inhalation anaesthetics
  • medicines used to treat heart failure, e.g. digoxin
  • theophylline, used to treat asthma and other related lung problems.

Check with your doctor or nurse if you are not sure about what medicines, vitamins or supplements you are taking and if these affect DBL Ephedrine Sulfate Injection.

4. How is DBL Ephedrine Sulfate Injection given?

How is DBL Ephedrine Sulfate Injection given

  • Your doctor will give you DBL Ephedrine Sulfate Injection by injection into a muscle, vein, or under the skin.

How much will be given

  • Your doctor will decide how much DBL Ephedrine Sulfate Injection you will be given and how long you will be given it.

If you are given too much DBL Ephedrine Sulfate Injection

As DBL Ephedrine Sulfate Injection doses are carefully worked out and given by a doctor experienced in its use, and you will be monitored carefully, it is extremely unlikely that you will be given too much.

Signs that you may have been given too much include headache, nausea, vomiting, dizziness, lightheadedness, emotional changes, hallucinations, blurred vision, chest pain or problems breathing. Tell your doctor or nurse immediately if you experience these.

5. What should I know during treatment with DBL Ephedrine Sulfate Injection?

Things you should do

Remind any doctor or nurse, that you have been given DBL Ephedrine Sulfate Injection.

Things you should not do

Driving or using machines

Your doctor will tell you when it is safe to drive and operate potentially dangerous machinery after you have been given DBL Ephedrine Sulfate Injection.

There is no information on the effects of this medicine on a person's ability to drive and use machines.

Drinking alcohol

No information available.

Looking after the medicine

DBL Ephedrine Sulfate Injection will be stored appropriately at the hospital.

Getting rid of any unwanted medicine

The hospital staff will dispose of any leftover DBL Ephedrine Sulfate Injection.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Side effects

Side effectsWhat to do
  • pale skin
  • fever or sweating
  • headache
  • dry nose, mouth and throat
  • difficulty sleeping
  • mood changes, irritability, nervousness, restlessness
Speak to your doctor or nurse if you have any of these side effects and they worry you.
  • difficult or painful urination/weeing
  • feeling sick, an upset stomach or vomiting
  • a feeling of pain or pressure in the chest
  • difficulty breathing or shortness of breath
  • a fast, slow or irregular heartbeat
  • dizziness, lightheadedness
  • abnormal thoughts or confusion
  • signs of an allergic reaction such as shortness of breath, wheezing or difficulty breathing; swelling of the face, lips, tongue, or other parts of the body; rash, itching or hives on the skin.
Speak to your doctor or nurse as soon as possible if you notice any of these side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side-effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/safety/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What DBL Ephedrine Sulfate Injection contains

Active ingredient
(main ingredient)		Ephedrine Sulfate
Other ingredients
(inactive ingredients)		Sodium Chloride
Water for injections

This medicine should not be used if you are allergic to any of these ingredients.

DBL Ephedrine Sulfate Injection does not contain lactose, sucrose, gluten, tartrazine or other azo dyes.

What DBL Ephedrine Sulfate Injection looks like

DBL Ephedrine Sulfate Injection is a clear colourless solution (AUST R 16325).

Who distributes DBL Ephedrine Sulfate Injection

Pfizer Australia Pty Ltd
Sydney NSW
Toll Free Number: 1800 675 229
www.pfizermedicalinformation.com.au

This leaflet was prepared in February 2025.

Published by MIMS April 2025

BRAND INFORMATION

Brand name

DBL Ephedrine Sulfate Injection

Active ingredient

Ephedrine sulfate

Schedule

S4

 

1 Name of Medicine

Ephedrine sulfate.

2 Qualitative and Quantitative Composition

DBL Ephedrine Sulfate Injection is a sterile solution of ephedrine sulfate in water for injections. Each mL contains 30 mg of ephedrine sulfate and 3 mg of sodium chloride in water for injections.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

DBL Ephedrine Sulfate is a clear colourless solution for injection.

4 Clinical Particulars

4.1 Therapeutic Indications

DBL Ephedrine Sulfate Injection is indicated in the treatment of shock unresponsive to fluid replacement. It is also indicated in the treatment of hypotension secondary to spinal anaesthesia.
DBL Ephedrine Sulfate Injection has also been used in the treatment of bronchial asthma and reversible bronchospasm although more selective agents (beta-adrenergic agonists) are now available.

4.2 Dose and Method of Administration

Dosage.

As a pressor.

Adult dose.

The usual adult dose is 25 to 50 mg (range 10 to 50 mg) administered intramuscularly or subcutaneously. Additional doses should be based on patient response. The intravenous route may be used if an immediate response is required. The dosage for the intravenous route is 10 to 25 mg which may be repeated every 5 to 10 minutes until the desired response is obtained.

Paediatric dose.

The recommended paediatric dose is 3 mg/kg/day or 100 mg/m2/day via the intravenous or subcutaneous route, given in 4 to 6 divided doses.
During therapy with a pressor agent, blood pressure should be elevated to slightly less than the patient's normal blood pressure. In previously normotensive patients, systolic blood pressure should be maintained at 80 to 100 mmHg. In previously hypertensive patients, systolic blood pressure should be maintained at 30 to 40 mmHg below their usual blood pressure. In some patients with very severe hypotension, maintenance of even lower blood pressure may be desirable if blood or fluid volume replacement has not been completed.
Bronchospasm.

Adult dose.

The usual adult dose is 12.5 to 25 mg, given intramuscularly, subcutaneously or intravenously. Further dosage should be determined by patient's response.

Paediatric dose.

The usual paediatric dose is 3 mg/kg or 100 mg/m2 intravenously or subcutaneously, given in 4 to 6 divided doses.

Method of administration.

DBL Ephedrine Sulfate Injection is administered by the intramuscular, subcutaneous or intravenous route. Patients in shock may require intravenous administration to ensure absorption of the drug. When administered intravenously, the injection should be given slowly. Care should be taken to avoid extravasation, since this may result in tissue necrosis and sloughing. Ephedrine sulfate should be administered in the lowest effective dose. The parenteral adult dose should not exceed 150 mg in 24 hours.

Compatibilities.

Ephedrine sulfate is reported to be compatible with 0.9% sodium chloride, lactated Ringer's injection, and 10% glucose in water.

4.3 Contraindications

DBL Ephedrine Sulfate Injection is contraindicated in closed angle glaucoma, since ephedrine may exacerbate the condition.
Ephedrine sulfate is contraindicated in patients with pheochromocytoma, since severe hypertension may result.
Ephedrine sulfate is contraindicated in patients with asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis) since the obstruction may increase as myocardial contractility improves.
Ephedrine sulfate is contraindicated in patients undergoing therapy with monoamine oxidase inhibitors (MAO inhibitors), or within 14 days of ceasing such therapy, since MAO inhibitors may prolong and intensify the cardiac and pressor effects of ephedrine.
Ephedrine sulfate is contraindicated in patients undergoing general anaesthesia with cyclopropane or halothane or other halogenated hydrocarbons, since anaesthesia may increase cardiac irritability which may lead to arrhythmias.
Ephedrine sulfate is contraindicated in patients with tachyarrhythmias or ventricular fibrillation, since exacerbation of these conditions may occur.
Ephedrine sulfate is also contraindicated in patients with hypersensitivity to ephedrine and in patients with psychoneurosis.

4.4 Special Warnings and Precautions for Use

The use of ephedrine as a pressor agent is not a substitute for replacement of blood, plasma, fluids and/or electrolytes. Blood volume depletion should be corrected as fully as possible before ephedrine therapy is instituted. In an emergency, ephedrine may be used as an adjunct to fluid volume replacement or as a temporary supportive measure to maintain coronary and cerebral artery perfusion until volume replacement therapy can be completed, but ephedrine must not be used as sole therapy in hypovolaemic patients.
Ephedrine may deplete noradrenaline stores in sympathetic nerve endings resulting in reduced cardiac and pressor effects of the drug. Consequently, it may be necessary to administer noradrenaline to replace tissue stores for restoration of the pressor effects of ephedrine.
Prolonged administration of pressor agents has been associated with oedema, haemorrhage, focal myocarditis, subpericardial haemorrhage, necrosis of the intestine and hepatic and renal necrosis. Since these effects have generally been observed in patients with severe shock and it is not clear if the drug or the shock state itself was responsible, they should therefore be taken into consideration before ephedrine sulfate is used.
Hypoxia, hypercapnia and acidosis may also reduce the effectiveness or increase the incidence of adverse effects of ephedrine, and should be identified and corrected prior to or concurrently with administration of the drug.
Ephedrine sulfate should be used with caution, if at all, in patients with hypertension or hyperthyroidism, since there is an increased risk of adverse effects in these patients.
Ephedrine sulfate should also be used with caution in diabetic patients since drug induced hyperglycaemia may result in loss of diabetic control.
Ephedrine sulfate should also be used with caution in patients with cardiovascular disease including angina, cardiac arrhythmia and coronary insufficiency, since the cardiovascular effects of ephedrine may exacerbate these conditions. Ephedrine may intensify the ischaemia in myocardial infarction by increasing myocardial oxygen demands.

Patient monitoring.

Cardiovascular parameters, including blood pressure, ECG, cardiac output, central venous pressure and pulmonary artery pressure should be monitored during therapy with ephedrine. Urinary output should also be monitored.

Use in the elderly.

Ephedrine sulfate should also be used with caution in geriatric males, especially those with prostatic hypertrophy, since ephedrine may cause acute urinary retention.

Paediatric use.

No data available.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Alpha-blockers.

Alpha-blockers may decrease the vasopressor effect of ephedrine.

Atropine sulfate.

Atropine sulfate may increase the vasopressor effect of ephedrine.

Beta-blockers.

Beta-blockers may inhibit the cardiac and bronchodilator effects of ephedrine.

Cardiac glycosides.

Concurrent use of cardiac glycosides and ephedrine may increase the risk of arrhythmias.

Ergotamine, ergometrine, methylergometrine, oxytocin.

Concurrent use of these drugs with ephedrine sulfate may result in a potentiation of the pressor effect of ephedrine. Concurrent use of ergotamine and ephedrine sulfate may also produce peripheral vascular ischaemia and gangrene.

Guanethidine.

Ephedrine sulfate may decrease the antihypertensive effect of guanethidine.

Hydrocarbon inhalation anaesthetics, such as cyclopropane, halothane.

These drugs may increase cardiac irritability, and concurrent use with ephedrine sulfate may lead to increased risk of arrhythmia (see Section 4.3 Contraindications).

Methyldopa.

Concurrent use of methyldopa with ephedrine sulfate may result in a reduced pressor effect.

Monoamine oxidase (MAO) inhibitors.

Concurrent use of MAO inhibitors and ephedrine sulfate may result in potentiation of the cardiac and pressor effects of ephedrine (see Section 4.3 Contraindications).

Reserpine.

Concurrent use of reserpine with ephedrine sulfate may result in a reduced pressor effect.

Sympathomimetic agents.

Concurrent use of ephedrine sulfate and other sympathomimetics may result in increased cardiovascular and pressor effects and an increased risk of adverse effects.

Tricyclic antidepressants.

Concurrent use of tricyclic antidepressant and ephedrine may result in potentiation of the cardiovascular and pressor effects of ephedrine.

Clonidine.

Pretreatment with clonidine may increase the pressor effect of ephedrine.

Urinary alkalinizers, such as acetazolamide, dichlorphenamide, sodium bicarbonate and sodium citrate.

These drugs may increase the half-life and decrease the elimination of ephedrine leading to enhanced therapeutic or toxic effects of ephedrine.

Theophylline.

Concurrent use of ephedrine and theophylline may result in an increased incidence of adverse effects than when either drug is used alone. Adverse effects include those in the central nervous and the gastrointestinal systems.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No data available.
(Category A)
Pregnancy Category A drug is defined by the Australian Drug Evaluation Committee as 'Drugs which have been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the foetus having been observed'.
DBL Ephedrine Sulfate Injection may accelerate the foetal heart rate when used to control maternal hypotension during spinal anaesthesia for delivery. DBL Ephedrine Sulfate Injection should not be used if the maternal blood pressure is greater than 130/80 mmHg.
 Ephedrine sulfate is distributed into breast milk, and therefore DBL Ephedrine Sulfate Injection is not recommended for use during lactation because of the risk of adverse effects in the infant.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Adverse Effects (Undesirable Effects)

Body as a whole.

Pallor, fever, headache, dryness of nose, mouth and throat.
Ephedrine sulfate is reported to cause physical addiction after excessive long-term use. Addiction is more likely to occur after oral use, since intramuscular, subcutaneous or intravenous administration of ephedrine sulfate would not normally occur over long periods.

Cardiovascular system.

Angina, palpitations, bradycardia, tachycardia, hypertension, hypotension, extrasystole and precordial pain. Arrhythmias, including ventricular fibrillation, may occur, especially in patients with organic heart disease or those receiving other drugs that sensitise the heart to arrhythmias.

Digestive system.

Nausea, vomiting, mild epigastric distress.

Nervous system.

Nervousness, anxiety, restlessness, insomnia, mood or mental changes, fear, irritability, trembling. Large doses may cause dizziness, lightheadedness, vertigo, confusion, delirium, euphoria. Long-term therapy in large doses may lead to psychosis characterized by paranoia, hallucinations, depression and bizarre mentation.

Genito-urinary system.

Difficult or painful urination, acute urinary retention (especially with prostatic hypertrophy).

Respiratory system.

Shortness of breath, respiratory difficulty, dyspnoea.

Skin and appendages.

Sweating.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

Clinical features.

Symptoms associated with overdosage of ephedrine include headache, severe nausea or vomiting, chills or fever, dizziness or lightheadedness, anxiety, nervousness, restlessness, mood changes, convulsions, severe weakness, blurred vision or enlarged pupils, ongoing fast heartbeat, severe or ongoing chest pain, severe hypertension or hypotension and severe breathing difficulties.
Paranoid psychosis, delusions and hallucinations may also follow ephedrine overdosage.

Treatment.

Treatment of overdose involves the following measures: reduce dosage or discontinue administration of ephedrine; general supportive therapy, including monitoring and maintaining vital signs, blood gases, electrolytes and ECG.
The following additional measures may need to be considered: beta-blockers (e.g. propranolol) to control tachycardia and arrhythmia; phentolamine or nitroprusside to reduce severe hypertension; diazepam to control convulsions. General anaesthesia and neuromuscular blocking agents may need to be considered to treat refractory seizures; dexamethasone to treat pyrexia.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia), 0800 764 766 (New Zealand).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Ephedrine is a sympathomimetic which stimulates both alpha and beta-adrenergic receptors, and also releases noradrenaline from storage site. The main effects of therapeutic doses of ephedrine are relaxation of bronchial smooth muscle, cardiac stimulation and increased systolic and usually diastolic blood pressure via an increase in cardiac output and peripheral vasoconstriction. Ephedrine also decreases intestinal tone and motility, relaxes the bladder wall, contracts the sphincter muscle, relaxes the detrusor muscle, and decreases uterine activity. Ephedrine also has central nervous system stimulant effects. Tachyphylaxis to the effects of ephedrine may also occur after use for a short while, possibly due to the depletion of noradrenaline stores.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

Absorption.

Ephedrine is rapidly absorbed after intramuscular or subcutaneous administration.

Distribution.

The onset of action after intramuscular administration is 10 to 20 minutes, and the duration of pressor and cardiac responses to ephedrine is 1 hour after intravenous administration of 10 to 25 mg or intramuscular or subcutaneous administration of 25 to 50 mg.

Metabolism.

Small quantities of ephedrine are metabolised in the liver, but the majority of ephedrine is excreted unchanged in the urine.

Excretion.

The plasma half-life of ephedrine is 3 to 6 hours. Elimination of ephedrine is increased (and hence the half-life is decreased) with decreasing pH of the urine. Ephedrine is presumed to cross the placenta and to be excreted into breast milk.

5.3 Preclinical Safety Data

Genotoxicity.

No data available.

Carcinogenicity.

No data available.

6 Pharmaceutical Particulars

6.1 List of Excipients

Sodium chloride; water for injections.

6.2 Incompatibilities

Ephedrine sulfate is reported to be physically incompatible with the phenobarbitone sodium, pentobarbitone sodium, quinalbarbitone sodium and thiopentone sodium, and with hydrocortisone sodium succinate in some infusion solutions.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C. Protect from light.

6.5 Nature and Contents of Container

Strength.

30 mg/mL.

Pack size.

5 x 1 mL ampoules.

Code.

8360B.

ARTG no.

AUST R 16325.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

The molecular formula of ephedrine sulfate is (C10H15NO)2.H2SO4. Its molecular weight is 428.5.

Chemical structure.


CAS number.

The CAS registry number of ephedrine sulfate is 134-72-5.

7 Medicine Schedule (Poisons Standard)

S4.

Summary Table of Changes